Basilea Pharmaceutica Ltd., of Basel, Swizterland, said the EMA accepted the marketing authorization application seeking approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis (zygomycosis) in adults. Basilea's co-development partner, Astellas Pharma Inc., of Tokyo, submitted a new drug application to the FDA in July.